US Patent 8,147,866: Claim Scope, Patent Landscape, Exclusivity and Generic-Entry Risk
US Patent 8,147,866 covers a buprenorphine oral transmucosal delivery platform with two defining technical features: a bioerodible mucoadhesive layer containing buprenorphine in a buffered polymeric environment at pH 4-6, and an adjacent barrier layer that directs drug movement toward the mucosal surface. The claims reach both the delivery device and methods of administering buprenorphine with that device.
The patent is narrower than a general buprenorphine film patent. Infringement requires a combination of drug, dosage form, pH range, mucoadhesive/bioerodible structure, and directional barrier function. Claims 6, 7, 11 and 12 add buprenorphine-antagonist combinations, particularly buprenorphine plus naloxone.
What does US Patent 8,147,866 protect?
The patent protects two related categories:
- Methods for enhanced buprenorphine uptake through direct transmucosal delivery.
- Mucoadhesive, bioerodable devices configured to deliver buprenorphine across an oral mucosal surface.
| Claim group |
Claim type |
Principal subject matter |
| Claims 1-7 |
Method claims |
Administration of buprenorphine through the claimed oral transmucosal device |
| Claims 2-3 |
Dependent method claims |
Narrower pH ranges |
| Claims 4-5 |
Dependent method claims |
Early plasma detection and at least four-hour effective concentration |
| Claims 6-7 |
Dependent method claims |
Addition of opioid antagonists, especially naloxone |
| Claims 8-12 |
Device claims |
The mucoadhesive bioerodable buprenorphine device and antagonist-containing versions |
The core independent claims are claims 1 and 8. They are materially similar, but claim 1 is directed to use of the device, while claim 8 is directed to the device itself.
What are the essential elements of independent claim 1?
Claim 1 requires all of the following limitations:
| Required element |
Scope |
| Active ingredient |
Buprenorphine |
| Administration route |
Direct transmucosal delivery to an oral mucosal surface |
| Dosage form |
Mucoadhesive bioerodable drug delivery device |
| Drug-containing layer |
Bioerodable mucoadhesive layer |
| Drug environment |
Buprenorphine disposed in a polymeric diffusion environment |
| pH |
Buffered environment having a pH of about 4 to about 6 |
| Barrier structure |
A polymeric barrier layer adjacent to the mucoadhesive layer |
| Directionality |
Barrier creates a unidirectional gradient toward the mucosal surface |
| Delivery result |
Buprenorphine passes across the buffered polymeric diffusion environment for rapid and efficient delivery |
A product that contains buprenorphine in an oral film but lacks the claimed buffered pH environment or adjacent directional barrier would have a strong non-infringement position under the literal language of claim 1.
The claim does not expressly require naloxone. Naloxone is an optional limitation appearing only in dependent claims 6, 7, 11 and 12. A buprenorphine-only product can therefore fall within claims 1 or 8 without satisfying the antagonist claims.
How narrow are the pH limitations?
Claims 2, 3, 9 and 10 narrow the pH requirement as follows:
| Claims |
Required pH |
| Claims 1 and 8 |
About 4 to about 6 |
| Claims 2 and 9 |
About 4.5 to about 5.5 |
| Claims 3 and 10 |
About 4.5 to about 5 |
The narrower claims are useful where a formulation has analytical data showing a pH within the tighter ranges. They may also create additional design-around opportunities. A formulation with a pH above 6 or below 4 would fall outside the literal scope of the independent claims, subject to claim construction and possible doctrine-of-equivalents arguments.
The phrase “polymeric diffusion environment” is important. The claim does not merely require that the finished film have a measured pH. The pH limitation attaches to the polymeric environment in which buprenorphine is disposed. A defendant may argue that the relevant pH is the formulation microenvironment, not the pH of a dissolution medium or the overall finished dosage form.
What does the barrier layer limitation require?
The barrier layer must be:
- polymeric;
- adjacent to the mucoadhesive layer; and
- configured to provide a unidirectional gradient when the device is applied to the mucosa.
The barrier is not simply a backing layer described by its physical presence. The claim assigns it a delivery function: directing buprenorphine across the diffusion environment toward the oral mucosa.
A multilayer film with a drug-containing adhesive layer and an impermeable or relatively less permeable backing layer presents the closest technical risk profile. A monolayer film, a tablet, a free-flowing powder, or a dissolving dosage form without the claimed adjacent polymeric barrier is less likely to satisfy the structural limitations.
What do claims 4 and 5 add?
Claims 4 and 5 impose pharmacokinetic performance limitations:
- Claim 4 requires a first quantifiable plasma concentration at about 45 minutes.
- Claim 5 requires an effective plasma concentration for at least four hours.
These limitations create evidentiary issues. Claim 4 does not specify a concentration threshold for “quantifiable.” Claim 5 does not define “effective plasma concentration.” Litigation would likely focus on the relevant analytical method, the patient population, dose, sampling schedule, and whether the result must occur in every administration or only in representative testing.
The claims also create potential enablement and definiteness issues if the terms are not sufficiently anchored to objective testing standards. Those issues depend on the intrinsic record, prosecution history and specification, not on the claim text alone. The Federal Circuit applies the full claim-construction record, including the specification and prosecution history, when determining the meaning of technical terms. [1]
What do the naloxone claims cover?
Claims 6, 7, 11 and 12 cover a device or method that combines buprenorphine with an opioid antagonist.
The listed antagonists include:
- naloxone;
- naltrexone;
- nalmefene;
- nalide;
- nalmexone;
- nalorphine;
- nalbuphine;
- cyclazocine; and
- levallorphan.
Claim 7 and claim 12 specifically narrow the antagonist to naloxone. These claims are relevant to buprenorphine/naloxone combination films, including products designed to reduce misuse by precipitating withdrawal or reducing opioid effects when administered by an unintended route.
A product containing buprenorphine and naloxone must still satisfy the underlying device architecture. The presence of naloxone alone does not establish infringement. The product must also have the claimed mucoadhesive bioerodable layer, buffered polymeric diffusion environment, pH range and adjacent barrier layer.
How does US Patent 8,147,866 compare with conventional Suboxone film patents?
US 8,147,866 should be analyzed as a platform or formulation-architecture patent rather than as a broad composition-of-matter patent.
| Patent category |
Typical protected subject matter |
Relevance to US 8,147,866 |
| Buprenorphine composition patents |
Chemical compound or salt |
Generally distinct from this patent |
| Buprenorphine/naloxone ratio patents |
Relative amounts of active ingredients |
May overlap commercially but not necessarily claim elements |
| Sublingual film patents |
Film composition, polymer matrix and drug loading |
Potentially overlapping |
| Mucoadhesive delivery patents |
Adhesion, erosion and transmucosal transport |
Closest technical category |
| Method-of-use patents |
Opioid-dependence treatment or dosing regimens |
Separate from the claimed device architecture |
| Manufacturing patents |
Casting, drying, layering and content uniformity |
Potentially separate blocking rights |
| Pediatric or dosing patents |
Dose, age, titration or administration schedule |
Usually separate from this patent |
The relevant competitive question is not whether a generic uses a film. It is whether the generic uses the specific multilayer, buffered, directional configuration claimed here.
What is the Orange Book significance?
FDA Orange Book listing and patent validity are separate issues. A patent can be technically relevant to a marketed product without appearing in the Orange Book, and an Orange Book-listed patent may be challenged through an Abbreviated New Drug Application Paragraph IV certification. FDA’s listing decisions depend on whether the patent claims the drug substance, drug product or an approved method of use in a manner eligible for listing under the applicable FDA regulations. [2]
For a buprenorphine/naloxone film:
- a product patent may be listed if it claims the approved dosage form or formulation;
- a method-of-use patent may be listed if it covers an approved use;
- a manufacturing-only patent generally has a different listing analysis;
- a patent directed to a delivery platform may require claim-by-claim review to determine whether it covers the approved product.
The patent number alone does not establish current Orange Book status. The FDA Orange Book patent table and the relevant reference-listed drug entry control the regulatory record. [2]
When does US Patent 8,147,866 lose exclusivity?
Patent term is determined by the relevant application filing chain, priority claims, patent term adjustment, patent term extension and any terminal disclaimer. It cannot be calculated reliably from the issued claims alone.
The practical exclusivity assessment should separate three dates:
| Exclusivity type |
Legal effect |
| Patent term |
Blocks conduct falling within valid, enforceable claims |
| FDA new-drug exclusivity |
Controls certain ANDA or 505(b)(2) submissions |
| Regulatory exclusivity tied to pediatric studies |
May delay approval independently of patent expiry |
If US 8,147,866 is listed for an approved reference product, a Paragraph IV certification could trigger the Hatch-Waxman litigation framework. A timely patent-infringement suit may impose a statutory stay of FDA approval for up to 30 months, subject to the statutory conditions and court developments. [3]
The patent’s effective market barrier may therefore extend beyond the date a challenger files an ANDA, but it cannot extend beyond the enforceable patent term. Regulatory exclusivity and patent term must be modeled separately.
What Paragraph IV risks exist for a buprenorphine/naloxone film?
A generic challenger would likely attack the patent through one or more of the following positions:
- The product lacks a buffered polymeric diffusion environment at pH 4-6.
- The product has no adjacent polymeric barrier layer.
- The barrier does not create a unidirectional gradient.
- The product is not bioerodable.
- The product is not sufficiently mucoadhesive.
- The pH is outside the claimed range.
- The asserted claims are anticipated by prior oral transmucosal films.
- The claims are obvious over film, mucoadhesive and transmucosal-delivery references.
- The pharmacokinetic terms in claims 4 and 5 are indefinite or not infringed.
- The patent is expired, terminally disclaimed or otherwise unenforceable.
The patent holder would counter that infringement is established by the product’s multilayer structure, formulation records, pH data, dissolution profile and permeability testing. Discovery would likely seek manufacturing specifications, batch records, design history files, regulatory submissions and analytical methods.
How strong is the patent estate?
The patent is strongest against products that closely replicate a multilayer buprenorphine film architecture with:
- a drug-containing mucoadhesive layer;
- an adjacent backing or barrier layer;
- a buffered pH between 4 and 6;
- oral mucosal placement; and
- buprenorphine, with or without naloxone.
Its scope is weaker against:
- sublingual tablets;
- buccal tablets;
- sprays;
- injectable products;
- implantable systems;
- monolayer films;
- films with no defined directional barrier; and
- formulations outside the claimed pH range.
The patent does not broadly monopolize buprenorphine treatment, buprenorphine/naloxone therapy, or every transmucosal dosage form. Its value depends on how closely competing products reproduce the claimed structure.
What manufacturing and intellectual-property barriers remain?
A competitor may avoid literal infringement while still facing other patent barriers. A commercial film may require separate freedom-to-operate analysis for:
- polymer selection;
- film casting and drying;
- multilayer registration;
- active-ingredient uniformity;
- solvent systems;
- taste masking;
- moisture control;
- packaging;
- dose-content uniformity;
- manufacturing scale-up; and
- approved labeling.
A design-around that removes the barrier layer may create new risks involving dose dumping, mucosal irritation, content uniformity or bioequivalence. A design-around that changes pH may alter buprenorphine dissolution, absorption and stability. These technical tradeoffs can make a narrow patent commercially important even when it does not block every alternative dosage form.
Which companies are relevant to the competitive landscape?
The principal commercial reference point is Indivior’s Suboxone buprenorphine/naloxone sublingual film. Generic competition has involved manufacturers pursuing ANDA approval for buprenorphine/naloxone film products, including major generic companies and specialty pharmaceutical firms. The relevant companies vary by product, litigation posture and FDA approval status.
The competitive analysis should distinguish:
| Company type |
Main risk |
| Reference-product sponsor |
Patent enforcement and Orange Book strategy |
| ANDA applicants |
Paragraph IV litigation and design-around exposure |
| 505(b)(2) developers |
Formulation and clinical bridging requirements |
| Film technology licensors |
Manufacturing and platform-IP licensing |
| API suppliers |
Salt, purity and supply-chain exposure |
Licensing arrangements may transfer formulation, film-manufacturing or territorial rights without transferring every patent in the estate. A license to a film platform does not necessarily grant freedom to operate for buprenorphine/naloxone products.
What litigation and settlement issues matter?
A complete litigation assessment requires review of PACER, district-court dockets, Federal Circuit decisions, PTAB proceedings and settlement filings. The claim language alone does not establish whether US 8,147,866 has been asserted, upheld, invalidated, disclaimed or licensed.
For diligence purposes, the relevant litigation questions are:
- Was the patent included in an ANDA notice letter?
- Was a Paragraph IV complaint filed within the statutory period?
- Was the patent dismissed or dropped from the case?
- Did the parties enter a licensed-entry settlement?
- Was an authorized generic commitment included?
- Did the court construe “unidirectional gradient” or “polymeric diffusion environment”?
- Was validity challenged under anticipation, obviousness, written description or enablement?
- Was a final judgment entered before patent expiry?
A settlement can remove litigation uncertainty without confirming claim validity. Entry timing, license scope, authorized-generic provisions and supply commitments determine the commercial impact.
Key Takeaways
- US 8,147,866 is directed to a specific buprenorphine oral transmucosal delivery architecture.
- Claims 1 and 8 are the central claims.
- The required combination is a bioerodable mucoadhesive buprenorphine layer, buffered polymeric diffusion environment at pH 4-6, and adjacent polymeric barrier layer creating directional delivery.
- Naloxone is optional under the independent claims and becomes mandatory only for the dependent antagonist claims.
- Claims 4 and 5 add pharmacokinetic performance limitations that may create infringement and definiteness disputes.
- The patent does not broadly cover all buprenorphine products, all buprenorphine/naloxone products or every oral film.
- The highest infringement risk is for multilayer buprenorphine or buprenorphine/naloxone films that replicate the claimed pH-controlled, directional mucoadhesive structure.
- Orange Book listing, current enforceability, terminal disclaimers, patent-term adjustment and litigation history require official record review separate from claim analysis.
- Generic applicants have plausible design-around paths through changes to film architecture, pH, barrier function, dosage form or administration route.
- The commercial value of the patent depends on its live term, listing status, prosecution history, asserted claim construction and overlap with the reference product.
FAQs About US Patent 8,147,866
Does US 8,147,866 cover Suboxone tablets?
Not automatically. The claims require a mucoadhesive bioerodable device with a buffered polymeric diffusion environment and adjacent barrier layer. A conventional sublingual tablet would generally require a separate claim-by-claim analysis.
Does a buprenorphine/naloxone film infringe automatically?
No. It must satisfy the structural and pH limitations of the asserted claim. Naloxone alone does not establish infringement.
Can a generic avoid the patent by changing the pH?
Potentially. A formulation outside the claimed pH range may avoid literal infringement, although the patent holder could assert an equivalents theory depending on the technical differences and prosecution history.
Are claims 4 and 5 composition claims?
No. They are dependent method claims. They impose plasma-concentration performance requirements on administration of the claimed device.
Does a barrier layer have to be completely impermeable?
The claim does not expressly require complete impermeability. It requires a polymeric barrier environment adjacent to the mucoadhesive layer that provides a unidirectional gradient for delivery toward the mucosal surface.
References
-
United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, § 2111: Claim interpretation; broadest reasonable interpretation. https://www.uspto.gov/web/offices/pac/mpep/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
21 U.S.C. § 355(j). Hatch-Waxman abbreviated new drug application provisions.
-
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,147,866: Buprenorphine delivery system. https://patents.google.com/patent/US8147866B2/en
